SINOMED(SH:688108)2024-04-26 10:26Financial Performance - The company's operating revenue for Q1 2024 was ¥91,062,636.90, representing a year-on-year increase of 24.46%[5] - The net profit attributable to shareholders was ¥2,498,599.75, with a significant increase of 115.42% compared to the previous year[9] - Total revenue for Q1 2024 reached ¥91,062,636.90, an increase of 24.5% compared to ¥73,168,207.49 in Q1 2023[17] - Net profit for Q1 2024 was ¥5,903,528.01, a significant recovery from a net loss of ¥18,642,741.10 in Q1 2023[18] - The operating profit for Q1 2024 was ¥1,129,993.81, a turnaround from an operating loss of ¥24,331,117.16 in Q1 2023[18] - The total comprehensive income for Q1 2024 was ¥4,584,583.90, recovering from a loss of ¥19,139,644.82 in Q1 2023[18] - The net profit for Q1 2024 was ¥3,887,572.99, compared to a net loss of ¥3,360,650.80 in Q1 2023, marking a significant turnaround[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,288,622,912.92, reflecting an increase of 8.67% from the end of the previous year[6] - The company's total equity rose to ¥892,997,123.44 in Q1 2024, up from ¥861,649,791.13 in Q1 2023[17] - The total liabilities increased to ¥395,625,789.48 in Q1 2024 from ¥324,171,588.85 in Q1 2023, marking a 22% increase[17] - The company's non-current assets totaled RMB 919,093,544.67, up from RMB 841,645,339.44, which is an increase of approximately 9.14%[15] - The total liabilities increased to ¥301,940,030.53 in Q1 2024 from ¥240,066,782.01 in Q1 2023, reflecting a 25.7% rise[24] Cash Flow - The net cash flow from operating activities was -¥16,218,315.41, indicating a negative cash flow situation[5] - Total cash inflow from operating activities in Q1 2024 was CNY 108,498,912.35, an increase of 25.7% from CNY 86,241,099.64 in Q1 2023[20] - Cash inflow from financing activities in Q1 2024 was CNY 87,527,487.94, significantly higher than CNY 17,000,000.00 in Q1 2023[20] - The company reported a cash outflow of CNY 34,980,905.10 from investing activities, compared to CNY 31,979,639.08 in Q1 2023[20] Research and Development - Research and development expenses totaled ¥40,560,514.19, accounting for 44.54% of operating revenue, which is an increase of 2.99 percentage points year-on-year[6] - Research and development expenses increased to ¥36,009,056.49 in Q1 2024, compared to ¥26,583,394.30 in Q1 2023, reflecting a 35.4% rise[17] - The company added Elum to its consolidated scope, contributing to increased R&D costs and operational expenses[9] - The company has ongoing development expenditures amounting to RMB 336,375,045.94, reflecting its commitment to innovation and product development[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,173[11] - The report indicates no significant changes in the shareholding structure among the top shareholders, maintaining stability in ownership[12] Earnings Per Share - The basic and diluted earnings per share were both ¥0.01, with a year-on-year increase of 125% attributed to the growth in net profit[9] - Basic earnings per share for Q1 2024 were CNY 0.01, compared to a loss of CNY 0.04 in Q1 2023[19] - The company achieved a basic earnings per share of ¥0.01 in Q1 2024, compared to a loss per share of ¥0.01 in Q1 2023[25]